@article{JGO12837,
author = {Kaloyan Yordanov and Simona Cima and Antonella Richetti and Gianfranco Pesce and Francesco Martucci and Ngwa Che Azinwi and Maria Carla Valli},
title = {Concurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer—acute toxicity and treatment outcome},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {2},
year = {2017},
keywords = {},
abstract = {Background: to report the acute toxicity and clinical results in patients with anal cancer treated with volumetric modulated arc therapy (VMAT) concomitant with chemotherapy.
Methods: A cohort of 21 patients with histologically confirmed squamous cell carcinoma of the anal canal was treated with VMAT and chemotherapy. Dose prescription was 39.6 Gy, 1.8 Gy/ fraction for the elective nodal PTV, the macroscopic (tumor and involved lymph nodes) PTV doses were 14.4 Gy up to a total dose of 54 Gy in 4 patients and 19.8 up to 59.4 Gy in 15 patients. One patient received a boost dose of 18 Gy up to a total dose of 57.6 Gy and another one was treated with 36 Gy and boost of 19.8 Gy up to a total dose of 55.8 Gy. Chemotherapy with MMC and 5-FU/Capecitabine was administered concomitantly. End points were local control (LC), disease-free survival (DFS) and overall survival (OS).
Results: Median follow-up time was 35.5 months. Two year OS was 91%, DFS was 73% and LRC was 81%. Acute dermatological toxicity G3 was recorded in one patient, ten patients (47.6%) experienced a G2 skin toxicity, while G1 toxicity was registered in eight patients (38%). One patient developed Grade 3 acute gastrointestinal (GI) toxicity, two patients (9.5%) experienced grade 2 acute GI toxicity and ten patients (47.6%) G1 toxicity. Acute genitourinary toxicity G1 was recorded in ten patients (47.6%).
Conclusions: Our results support VMAT as standard radiotherapy technique in the treatment of patients with anal cancer.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/12837}
}